Navigation Links
Laboratory Customers Name bioMerieux 'Top Of Class' for Microbiology
Date:12/17/2008

DURHAM, N.C., Dec. 17 /PRNewswire/ -- In a recent customer satisfaction survey of over 30,000 readers of ADVANCE for Administrators of the Laboratory, bioMerieux was voted by its customers as the "Top Of Class" winner for the microbiology category. The top-level lab managers and pathologists who subscribe to ADVANCE chose bioMerieux over other clinical laboratory suppliers because of the company's "great customer and technical support," "reliable instruments," and "quick response time."

Results of this survey were announced in the November issue of ADVANCE, with comments from readers on why they selected bioMerieux. The survey was conducted online at http://www.advanceweb.com between mid-June and mid-August, 2008. This year's survey had nearly 1,300 survey responses, primarily from top-level managers.

"The winners of our 'Top Of Class' survey are rated by readers of ADVANCE for Administrators of the Laboratory as the elite in their respective categories," said Lynn Nace, editor of ADVANCE for Administrators of the Laboratory. "And as such, they often raise the standard to improve the quality and accuracy of clinical laboratory testing and results reporting."

Microbiology was one of 13 categories polled by ADVANCE. For each category, readers were asked to fill in the name of the company they felt was top of the class and provide three reasons to support their nominations.

Published by Merion Publications Inc., ADVANCE for Administrators of the Laboratory is a medical laboratory and research specialty publication that boasts over 30,000 readers who manage labs or who support clinical labs. The monthly publication was founded in 1992 and provides original content for managers, directors, pathologists, and supervisors of clinical laboratories. For more information, visit http://www.advanceweb.com.

About bioMerieux

Advancing diagnostics to improve public health

A world leader in the field of in vitro diagnostics for over 45 years, bioMerieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2007, revenues reached euro 1.063 billion with 84% of sales outside of France.

bioMerieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Our products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMerieux is listed on the NYSE Euronext Paris market (Symbol: BIM - ISIN: FR0010096479). Other information can be found at http://www.biomerieux.com.


'/>"/>
SOURCE bioMerieux
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
2. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
3. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
4. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies
5. AviaraDx Announces CAP Accreditation of Its Laboratory Operations
6. Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use for HemosIL(R) D-Dimer HS Assay
7. New White Paper Details Six Steps to Investigate and Prevent Laboratory Accidents
8. Codexis Opens Singapore Laboratory
9. Stem Cell Leader Beike Biotech and Chinas Tsinghua University Receive US$4 Million for Stem Cell Reprogramming Laboratory
10. Ames Laboratory researchers solve fuel-cell membrane structure conundrum
11. HealthTrust Expands Contract With Instrumentation Laboratory for Critical Care Portfolio to Include Consorta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... ... of antibody therapeutics from millions-diverse immune repertoires, today announced a strategic partnership with ... strains genetically engineered to express human antibodies. The partnership will use GigaGen technology ...
(Date:2/28/2017)... , Feb. 28, 2017  ITL Limited ... company, supplier and strategic partner that provides innovative ... individual health management, formally announces its rebrand to ... name change is part of the Company,s unified ... launch of an integrated corporate website, ITLHealthGroup.com ...
(Date:2/28/2017)... and NEW YORK , February ... License Application accepted by the FDA for avelumab  ... disease has metastasized   ... Germany , in the US and ... US Food and Drug Administration (FDA) has accepted for Priority ...
(Date:2/27/2017)... -- A Europe-wide survey of institutes conducted by the ... their research treat them with due care. The survey polled a ... the results indicates that there is a strong commitment among animal ... the principles of the 3Rs (Refine, Reduce, Replace)  ... What are the 3Rs? ...
Breaking Biology Technology:
(Date:2/13/2017)... 2017  RSA Conference -- RSA, a Dell Technologies ... to enhance fraud detection and investigation across digital ... Fraud & Risk Intelligence Suite. The new platform ... insights from internal and external sources as well ... customers from targeted cybercrime attacks. "Fraudsters ...
(Date:2/9/2017)... Feb. 9, 2017 The biomass boiler market ... the biomass boiler market globally in terms of revenue ... boilers. The market for biomass boilers has been segmented ... application, and country/region. The market based on feedstock type, ... residues, biogas & energy crops, urban residues, and others. ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global ... reach $11.4 billion by 2021, growing at a compound annual ... - An overview of the global markets for synthetic biology. ... estimates for 2016, and projections of compound annual growth rates ...
Breaking Biology News(10 mins):